NASDAQ:APRE
Aprea Therapeutics, Inc.
- Stock
Last Close
3.81
26/07 20:00
Market Cap
21.45M
Beta: -
Volume Today
3.70K
Avg: 15.86K
PE Ratio
−0.19
PFCF: −1.88
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | ||||||||
average payables | 1.70M - | 1.96M 15.14% | 3.34M 70.59% | 3.14M 6.04% | 1.31M 58.33% | 1.26M 3.92% | ||
average receivables | ||||||||
book value per share | -50.82 - | -73.09 43.82% | 413.97 666.43% | 73.24 82.31% | 46.51 36.49% | 15.48 66.73% | 4.69 69.72% | |
capex per share | -0.01 - | -0.10 1,857.38% | -0.02 76.37% | -0.03 - | ||||
capex to depreciation | -0.45 - | -0.18 59.23% | -0.11 38.31% | -13.20 - | ||||
capex to operating cash flow | 0.00 - | 0.00 376.61% | 0.00 46.84% | 0.01 - | ||||
capex to revenue | ||||||||
cash per share | 34.67 - | 93.32 169.15% | 433.45 364.49% | 84.24 80.56% | 49.87 40.80% | 17.37 65.16% | 5.97 65.62% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | ||||||||
debt to assets | 0.00 - | 0.00 11.46% | 0.00 7.18% | |||||
debt to equity | 0.00 - | 0.00 1.27% | 0.00 11.16% | |||||
dividend yield | ||||||||
earnings yield | -0.05 - | -0.05 2.23% | -0.10 78.13% | -0.52 440.94% | -0.60 15.33% | -20.50 3,327.72% | -0.84 95.90% | |
enterprise value | 264.15M - | 222.88M 15.63% | 145.91M 34.53% | 15.29M 89.52% | 8.21M 46.34% | -17.82M 317.10% | -4.60M 74.16% | |
enterprise value over ebitda | -16.00 - | -13.52 15.49% | -4.73 65.05% | -0.29 93.77% | -0.22 26.23% | -0.46 113.69% | 0.30 164.08% | |
ev to operating cash flow | -18.86 - | -14.61 22.53% | -5.46 62.62% | -0.37 93.30% | -0.22 40.48% | 0.71 427.13% | 0.38 46.93% | |
ev to sales | ||||||||
free cash flow per share | -19.90 - | -21.67 8.94% | -89.10 311.07% | -39.58 55.57% | -35.41 10.55% | -15.09 57.37% | -3.39 77.53% | |
free cash flow yield | -0.05 - | -0.05 8.94% | -0.10 83.63% | -0.40 314.41% | -0.62 53.34% | -2.28 269.61% | -0.72 68.35% | |
graham net net | -51.33 - | -73.58 43.34% | 402.25 646.70% | 69.66 82.68% | 42.99 38.28% | 14.65 65.93% | 4.40 69.98% | |
graham number | 157.10 - | 190.48 21.25% | 905.26 375.25% | 289.98 67.97% | 189.55 34.63% | 217.38 14.68% | 20.41 90.61% | |
income quality | 0.92 - | 0.98 6.54% | 0.95 3.08% | 0.78 17.88% | 1.02 29.86% | 0.22 78.13% | 0.85 283.95% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -1.06M - | -90.60K 91.43% | -198.54 99.78% | -234.22 17.97% | 85.10 - | |||
interest debt per share | 0.00 - | 0.00 1,113.33% | 2.34 903,489.38% | 0.53 77.41% | 0.18 66.10% | 0.27 51.30% | ||
inventory turnover | ||||||||
invested capital | 0.00 - | 0.00 1.27% | 0.00 11.16% | |||||
market cap | 288.55M - | 288.55M 0% | 275.45M 4.54% | 103.98M 62.25% | 61.09M 41.24% | 10.97M 82.04% | 17.00M 55.00% | |
net current asset value | -35.80M - | -51.46M 43.76% | 123.68M 340.34% | 77.01M 37.74% | 49.27M 36.02% | 25.64M 47.96% | 16.82M 34.39% | |
net debt to ebitda | 1.48 - | 3.98 169.56% | 4.20 5.30% | 1.71 59.29% | 1.40 18.01% | -0.75 153.58% | 1.40 286.13% | |
net income per share | -21.58 - | -22.06 2.23% | -87.98 298.75% | -51.02 42.00% | -34.33 32.72% | -135.71 295.32% | -3.95 97.09% | |
operating cash flow per share | -19.90 - | -21.67 8.91% | -88.99 310.69% | -39.56 55.55% | -35.41 10.49% | -15.09 57.37% | -3.37 77.70% | |
payables turnover | ||||||||
receivables turnover | ||||||||
research and ddevelopement to revenue | ||||||||
return on tangible assets | -0.61 - | -0.24 61.66% | -0.20 15.97% | -0.58 193.97% | -0.64 10.67% | -7.46 1,059.77% | -0.63 91.54% | |
revenue per share | ||||||||
roe | 0.42 - | 0.30 28.92% | -0.21 170.40% | -0.70 227.79% | -0.74 5.94% | -8.77 1,088.23% | -0.84 90.39% | |
roic | 0.42 - | 0.34 19.69% | -0.23 168.47% | -0.67 188.97% | -0.75 11.40% | 2.97 496.09% | -0.91 130.71% | |
sales general and administrative to revenue | ||||||||
shareholders equity per share | -50.82 - | -73.09 43.82% | 413.97 666.43% | 73.24 82.31% | 46.51 36.49% | 15.48 66.73% | 4.69 69.72% | |
stock based compensation to revenue | ||||||||
tangible asset value | -35.77M - | -51.44M 43.82% | 124.24M 341.55% | 77.40M 37.71% | 49.51M 36.03% | 25.64M 48.20% | 16.95M 33.89% | |
tangible book value per share | -50.82 - | -73.09 43.82% | 413.97 666.43% | 73.24 82.31% | 46.51 36.49% | 15.48 66.73% | 4.69 69.72% | |
working capital | 20.43M - | 61.13M 199.21% | 123.98M 102.82% | 77.09M 37.83% | 49.27M 36.09% | 26.95M 45.29% | 18.14M 32.71% |
All numbers in USD (except ratios and percentages)